CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report

BACKGROUND: Chimeric antigen receptor-modified T cells (CAR-T) targeting CD19 has produced a high durable response in refractory or relapsed diffuse large B-cell lymphoma. Besides well-known cytokine release syndrome (CRS) or immune effector cell–associated neurotoxicity syndrome during CAR-T cell t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Zhuanyi, Xie, Caiqin, Liu, Hui, Yuan, Xianggui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829460/
https://www.ncbi.nlm.nih.gov/pubmed/35154102
http://dx.doi.org/10.3389/fimmu.2022.778192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829460/
https://www.ncbi.nlm.nih.gov/pubmed/35154102
http://dx.doi.org/10.3389/fimmu.2022.778192

Ejemplares similares